Resumen de acción

Trading at 82.3% below our estimate of its fair value

Earnings are forecast to grow 20.53% per year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 30.9%

Profit margins (5.4%) are lower than last year (11.3%)

Significant insider selling over the past 3 months

Dividend of 2.22% is not well covered

No hay actualizaciones

No hay actualizaciones

	DSM2	Chemicals	Mercado
7D	0.3%	0%	0%
1Y	-28.1%	0%	0%

Rentabilidad vs. Industria: DSM2 underperformed the German Chemicals industry which returned -12.6% over the past year.

Rentabilidad vs. Mercado: DSM2 underperformed the German Market which returned -8.2% over the past year.

Is DSM2's price volatile compared to industry and market?
DSM2 volatility
DSM2 Average Weekly Movement	3.4%
Chemicals Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in DE Market	0%
10% least volatile stocks in DE Market	0%

Precio estable de las acciones: DSM2 has not had significant price volatility in the past 3 months.

Volatilidad a lo largo del tiempo: DSM2's weekly volatility (3%) has been stable over the past year.

Fundada	Empleados	CEO	Página web
1902	19,973	Dimitri de Vreeze	n/a

¿Cómo se comparan los beneficios e ingresos de DSM-Firmenich con su capitalización de mercado?
Estadísticas fundamentales de DSM2
Capitalización bursátil	n/a
Beneficios(TTM)	0
Ingresos (TTM)	n/a

Ratio precio-beneficio (PE)

Ratio precio-ventas (PS)

¿Está DSM2 sobrevalorada?

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de DSM2
Ingresos	US$8.39b
Coste de los ingresos	US$5.70b
Beneficio bruto	US$2.69b
Otros gastos	US$2.24b
Beneficios	US$454.00m

Últimos beneficios comunicados

n/a

Próxima fecha de beneficios

n/a

¿Cómo se ha desempeñado DSM2 a largo plazo?